Your browser doesn't support javascript.
loading
Preferential interaction of platelets with prostate cancer cells with stem cell markers.
Rudzinski, Jan K; Govindasamy, Natasha P; Asgari, Amir; Saito, Max S; Lewis, John D; Jurasz, Paul.
Afiliación
  • Rudzinski JK; Division of Urology, Department of Surgery, University of Alberta, Canada.
  • Govindasamy NP; Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Canada.
  • Asgari A; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada.
  • Saito MS; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada.
  • Lewis JD; Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Canada.
  • Jurasz P; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada; Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Canada; Cardiovascular Research Centre, University of Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Can
Thromb Res ; 206: 42-51, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34403851
BACKGROUND: Prostate cancer (PCa) may be initiated by CD133+/CD44+ expressing stem cell-like cells (PCSC), which are also thought to drive metastasis. Platelets also contribute to metastasis via tumor cell-induced platelet aggregation (TCIPA), which in part enhances cancer cell invasion. Moreover, activated platelets secrete stromal derived growth factor-1α (SDF-1α) that can mobilize CSCs via the CXCR4 receptor. However, the potential reciprocal interactions between CSCs and platelets have not been investigated. OBJECTIVE: To characterize the mechanisms behind PCSC-platelet interaction. METHODS: Fluorescence Activated Cell Sorting was utilized to separate DU145 and PC3 PCa cells into CD133+/CD44+, CD133+/CD44-, CD44+/CD133-, and CD133-/CD44- subpopulations and to measure their CXCR4 surface expression. PCa subpopulation TCIPA experiments were performed using aggregometry and immunoblot was used to measure prothrombin. Platelet SDF-1α secretion was measured by ELISA. Modified-Boyden chamber assays were used to assess the role of SDF-1α:CXCR4 pathway in platelet-PCSC interactions. RESULTS: DU145 and PC3 expressing both CD133 and CD44 stem cell markers accounted for only small fractions of total cells (DU145: CD133+/CD44+ 3.44 ± 1.45% vs. CD133+/CD44- 1.56 ± 0.45% vs. CD44+/CD133- 68.19 ± 6.25% vs. CD133-/CD44- 20.36 ± 4.51%). However, CD133+ subpopulations induced the greatest amount of aggregation compared to CD44+/CD133- and double-negative DU145, and this aggregation potency of CD133+ PCa cells corresponded with high levels of prothrombin expression. Additionally, CD133+ subpopulations expressed significantly higher level of CXCR4 compared to CD133-/CD44- and CD44+/CD133-. Disruption of SDF-1α:CXCR4 pathway reduced platelet-induced PCSC invasion. CONCLUSIONS: CD133+/CD44+ and CD133+/CD44- PCSCs have highest platelet aggregation potency, which could be attributed to their increased prothrombin expression. Reciprocally, platelet-derived SDF-1α stimulates PCSC invasion.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Plaquetas Idioma: En Revista: Thromb Res Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Plaquetas Idioma: En Revista: Thromb Res Año: 2021 Tipo del documento: Article